Tags

Type your tag names separated by a space and hit enter

Reduced relative risk of fractures among users of lithium.
Calcif Tissue Int 2005; 77(1):1-8CT

Abstract

Lithium has been shown to inhibit bone resorption and to interact with W nt signaling, potentially pointing to bone anabolic properties. We, therefore, studied the effects of lithium on fracture risk using a case-control study design. Cases were all subjects including children with any fracture sustained during the year 2000 (n=124,655). For each case, three controls (n=373,962) matched according to age and gender was randomly drawn from the background population. Adjustments were made for use of other psychotropic drugs (neuroleptics, antidepressants, and anxiolytics/sedatives), psychiatric disease (manic depressive states, schizophrenia, and other psychoses), and other confounders. The effect of dose was examined by stratifying for cumulated dose (DDD, defined daily dose). In the crude analysis, there was a decreasing relative risk of any fracture with increasing accumulated dose of lithium. After adjustment for psychotropic drug use, the risk of any fracture was decreased (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.60--0.92 for 250--849 DDD, and OR 0.67, 95% CI 0.55--0.81 for >or= 850 DDD of lithium). For Colles' fractures and spine fractures, a significant decrease was seen with >or= 850 DDD (OR 0.57, 95% CI 0.35--0.94 for Colles' fracture and OR 0.32, 95% CI 0.11--0.95 for spine fractures). For hip fractures, a nonsignificant trend toward a decrease was seen; however, without a dose-response relationship. Adjustment for further confounders did not change the results. Lithium treatment was associated with a decreased risk of fractures potentially pointing at bone anabolic properties.

Authors+Show Affiliations

Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus Sygehus, Aarhus, Denmark. p-vest@post4.tele.dkNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16007481

Citation

Vestergaard, P, et al. "Reduced Relative Risk of Fractures Among Users of Lithium." Calcified Tissue International, vol. 77, no. 1, 2005, pp. 1-8.
Vestergaard P, Rejnmark L, Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif Tissue Int. 2005;77(1):1-8.
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2005). Reduced relative risk of fractures among users of lithium. Calcified Tissue International, 77(1), pp. 1-8.
Vestergaard P, Rejnmark L, Mosekilde L. Reduced Relative Risk of Fractures Among Users of Lithium. Calcif Tissue Int. 2005;77(1):1-8. PubMed PMID: 16007481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced relative risk of fractures among users of lithium. AU - Vestergaard,P, AU - Rejnmark,L, AU - Mosekilde,L, Y1 - 2005/07/14/ PY - 2004/11/12/received PY - 2005/02/04/accepted PY - 2005/7/12/pubmed PY - 2005/11/16/medline PY - 2005/7/12/entrez SP - 1 EP - 8 JF - Calcified tissue international JO - Calcif. Tissue Int. VL - 77 IS - 1 N2 - Lithium has been shown to inhibit bone resorption and to interact with W nt signaling, potentially pointing to bone anabolic properties. We, therefore, studied the effects of lithium on fracture risk using a case-control study design. Cases were all subjects including children with any fracture sustained during the year 2000 (n=124,655). For each case, three controls (n=373,962) matched according to age and gender was randomly drawn from the background population. Adjustments were made for use of other psychotropic drugs (neuroleptics, antidepressants, and anxiolytics/sedatives), psychiatric disease (manic depressive states, schizophrenia, and other psychoses), and other confounders. The effect of dose was examined by stratifying for cumulated dose (DDD, defined daily dose). In the crude analysis, there was a decreasing relative risk of any fracture with increasing accumulated dose of lithium. After adjustment for psychotropic drug use, the risk of any fracture was decreased (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.60--0.92 for 250--849 DDD, and OR 0.67, 95% CI 0.55--0.81 for >or= 850 DDD of lithium). For Colles' fractures and spine fractures, a significant decrease was seen with >or= 850 DDD (OR 0.57, 95% CI 0.35--0.94 for Colles' fracture and OR 0.32, 95% CI 0.11--0.95 for spine fractures). For hip fractures, a nonsignificant trend toward a decrease was seen; however, without a dose-response relationship. Adjustment for further confounders did not change the results. Lithium treatment was associated with a decreased risk of fractures potentially pointing at bone anabolic properties. SN - 0171-967X UR - https://www.unboundmedicine.com/medline/citation/16007481/Reduced_relative_risk_of_fractures_among_users_of_lithium_ L2 - https://dx.doi.org/10.1007/s00223-004-0258-y DB - PRIME DP - Unbound Medicine ER -